[125I]iodomelatonin binding sites in spleens of birds and mammals

Influence of Different Light Spectra on Melatonin Synthesis by the Pineal Gland and Influence on the Immune System in Chickens

It is well known that the pineal gland in birds influences behavioural and physiological functions, including those of the immune system. The purpose of this research is to examine the endocrine-immune correlations between melatonin and immune system activity. Through a description of the immune-pineal axis, we formulated the objective to determine and describe: the development of the pineal gland; how light influences secretory activity; and how melatonin influences the activity of primary and secondary lymphoid organs. The pineal gland has the ability to turn light information into an endocrine signal suitable for the immune system via the membrane receptors Mel1a, Mel1b, and Mel1c, as well as the nuclear receptors RORα, RORβ, and RORγ. We can state the following findings: green monochromatic light (560 nm) increased serum melatonin levels and promoted a stronger humoral and cellular immune response by proliferating B and T lymphocytes; the combination of green and blue monochromatic light (560-480 nm) ameliorated the inflammatory response and protected lymphoid organs from oxidative stress; and red monochromatic light (660 nm) maintained the inflammatory response and promoted the growth of pathogenic bacteria. Melatonin can be considered a potent antioxidant and immunomodulator and is a critical element in the coordination between external light stimulation and the body's internal response.

Effects of dietary tryptophan on the antioxidant capacity and immune response associated with TOR and TLRs/MyD88/NF-κB signaling pathways in northern snakehead, Channa argus (Cantor, 1842)

Introduction

Dietary tryptophan (Trp) has been shown to influence fish feed intake, growth, immunity and inflammatory responses. The purpose of this study was to investigate the effect and mechanism of Trp on immune system of juvenile northern snakehead (Channa argus Cantor, 1842).

Methods

A total of 540 fish (10.21 ± 0.11 g) were fed six experimental diets containing graded levels of Trp at 1.9, 3.0, 3.9, 4.8, 5.9 and 6.8 g/kg diet for 70 days, respectively.

Results and Discussion

The results showed that supplementation of 1.9-4.8 g/kg Trp in diets had no effect on the hepatosomatic index (HSI) and renal index (RI), while dietary 3.9 and 4.8 g/kg Trp significantly increased spleen index (SI) of fish. Dietary 3.9, 4.8, 5.9 and 6.8 g/kg Trp enhanced the total hemocyte count (THC), the activities of total antioxidant capacity (T-AOC) and superoxide dismutase (SOD). Malondinaldehyde (MDA) levels in the blood were significantly decreased by consuming 3.9 and 4.8 g/kg Trp. Fish fed with 3.0 and 3.9 g/kg Trp diets up-regulated interleukin 6 (il-6) and interleukin 8 (il-8) mRNA levels. The expression of tumor necrosis factor α (tnf-α) was highest in fish fed with 3.0 g/kg Trp diet, and the expression of interleukin 1β (il-1β) was highest in fish fed with 3.9 g/kg Trp diet. Dietary 4.8, 5.9 and 6.8 g/kg Trp significantly decreased il-6 and tnf-α mRNA levels in the intestine. Moreover, Trp supplementation was also beneficial to the mRNA expression of interleukin 22 (il-22). Additionally, the mRNA expression levels of target of rapamycin (tor), toll-like receptor-2 (tlr2), toll-like receptor-4 (tlr4), toll-like receptor-5 (tlr5) and myeloid differentiation primary response 88 (myd88) of intestine were significantly up-regulated in fish fed 1.9, 3.0 and 3.9 g/kg Trp diets, and down-regulated in fish fed 4.8, 5.9 and 6.8 g/kg Trp diets. Dietary 4.8 and 5.9 g/kg Trp significantly increased the expression of inhibitor of nuclear factor kappa B kinase beta subunit (ikkβ) and decreased the expression of inhibitor of kappa B (iκbα), but inhibited nuclear transcription factor kappa B (nf-κb) mRNA level. Collectively, these results indicated that dietary 4.8 g/kg Trp could improve antioxidant capacity and alleviate intestinal inflammation associated with TOR and TLRs/MyD88/NF-κB signaling pathways.

The role of melatonin in the cells of the innate immunity: a review

Melatonin is the major secretory product synthesized and secreted by the pineal gland and shows both a wide distribution within phylogenetically distant organisms from bacteria to humans and a great functional versatility. In recent years, a considerable amount of experimental evidence has accumulated showing a relationship between the nervous, endocrine, and immune systems. The molecular basis of the communication between these systems is the use of a common chemical language. In this framework, currently melatonin is considered one of the members of the neuroendocrine-immunological network. A number of in vivo and in vitro studies have documented that melatonin plays a fundamental role in neuroimmunomodulation. Based on the information published, it is clear that the majority of the present data in the literature relate to lymphocytes; thus, they have been rather thoroughly investigated, and several reviews have been published related to the mechanisms of action and the effects of melatonin on lymphocytes. However, few studies concerning the effects of melatonin on cells belonging to the innate immunity have been reported. Innate immunity provides the early line of defense against microbes and consists of both cellular and biochemical mechanisms. In this review, we have focused on the role of melatonin in the innate immunity. More specifically, we summarize the effects and action mechanisms of melatonin in the different cells that belong to or participate in the innate immunity, such as monocytes-macrophages, dendritic cells, neutrophils, eosinophils, basophils, mast cells, and natural killer cells.

A review of the multiple actions of melatonin on the immune system

This review summarizes the numerous observations published in recent years which have shown that one of the most significant of melatonin's pleiotropic effects is the regulation of the immune system. The overview summarizes the immune effects of pinealectomy and the association between rhythmic melatonin production and adjustments in the immune system as markers of melatonin's immunomodulatory actions. The effects of both in vivo and in vitromelatonin administration on non-specific, humoral, and cellular immune responses as well as on cellular proliferation and immune mediator production are presented. One of the main features that distinguishes melatonin from the classical hormones is its synthesis by a number of non-endocrine extrapineal organs, including the immune system. Herein, we summarize the presence of immune system-synthesized melatonin, its direct immunomodulatory effects on cytokine production, and its masking effects on exogenous melatonin action. The mechanisms of action of melatonin in the immune system are also discussed, focusing attention on the presence of membrane and nuclear receptors and the characterization of several physiological roles mediated by some receptor analogs in immune cells. The review focuses on melatonin's actions in several immune pathologies including infection, inflammation, and autoimmunity together with the relation between melatonin, immunity, and cancer.

Tryptophan consumption and indoleamines production by peritoneal cavity macrophages

Melatonin has been shown to regulate several immune functions, and some authors showed that leukocytes are also able to produce the indolamine. In fact, it seems to take part in some immunoregulatory axis, including that related to interferon (IFN) production. So, we evaluated the rate of tryptophan consumption and melatonin and serotonin production in peritoneal cavity-isolated macrophages and the effect of IFN-alpha and -gamma, lipopolysaccharide (LPS), and phorbol myristate acetate (PMA) on such parameters. Our results indicate that macrophages obtained from the peritoneal cavity of normal rats when incubated with tryptophan show an increase in arylalkylamine N-acetyltransferase activity that corresponds to an increased melatonin production, as determined in the incubation medium. This process is regulated by IFN-alpha and -gamma, PMA, LPS, and the serum from tumor-bearing rats, opening the possibility of speculation about different immunoregulatory loops acting through the balance of melatonin/serotonin production by such cells.

Melatonin potentiates phenylephrine-stimulated intracellular Ca2+ transient in smooth muscle cell of large arteries of chick embryo

In the current study we first characterized the properties of the 2-[125I]iodomelatonin binding in pulmonary artery and aorta of chick embryo, and then determined the location of the binding site with autoradiography. Receptor binding assays were used using 2-[125I]iodomelatonin as ligand. The binding was stable, saturable, specific and reversible. Scatchard anlaysis revealed an equilibrium binding constant (Kd) of 27.12 +/- 1.34 pM and a maximum binding capacity (Bmax) of 1.93 +/- 0.19 fmol/mg protein (n = 5). Guanosine 5'-O-(3-thiotriphosphate) (GTPgammaS) increased the Kd, but reduced the Bmax, indicating the binding being coupled to a G-protein. Autoradiography revealed the binding sites in the smooth muscle layer. To delineate the physiological function of melatonin in the large artery of the chick embryo, we determined the intracellular calcium ([Ca2+]i) in smooth muscle cells of the aorta with spectrofluorometry, using fura 2-AM as calcium indicator. Melatonin at 10(-8) to 10(-5), which itself had no effect, potentiated the stimulating effect of 0.1 microM phenylephrine, a selective agonist of alpha -adrenoceptor, on [Ca2+]i. In conclusion, specific binding of 2-[125I]iodomelatonin and physiological response to melatonin suggest the existence of melatonin receptor in the smooth muscle of large arteries of the chick embryo. Melatonin potentiates the effects of alpha1-adrenergic stimulation.

Melatonin enhancement of splenocyte proliferation is attenuated by luzindole, a melatonin receptor antagonist

In addition to marked seasonal changes in reproductive, metabolic, and other physiological functions, many vertebrate species undergo seasonal changes in immune function. Despite growing evidence that photoperiod mediates seasonal changes in immune function, little is known regarding the neuroendocrine mechanisms underlying these changes. Increased immunity in short days is hypothesized to be due to the increase in the duration of nightly melatonin secretion, and recent studies indicate that melatonin acts directly on immune cells to enhance immune parameters. The present study examined the contribution of melatonin receptors in mediating the enhancement of splenocyte proliferation in response to the T cell mitogen Concanavalin A in mice. The administration of luzindole, a high-affinity melatonin receptor antagonist, either in vitro or in vivo significantly attenuated the ability of in vitro melatonin to enhance splenic lymphocyte proliferation during the day or night. In the absence of melatonin or luzindole, splenocyte proliferation was intrinsically higher during the night than during the day. In the absence of melatonin administration, luzindole reduced the ability of spleen cells to proliferate during the night, when endogenous melatonin concentrations are naturally high. This effect was not observed during the day, when melatonin concentrations are low. Taken together, these results suggest that melatonin enhancement of splenocyte proliferation is mediated directly by melatonin receptors on splenocytes and that there is diurnal variation in splenocyte proliferation in mice that is also mediated by splenic melatonin receptors.

Melatonin receptors and melatonin inhibition of duck salt gland secretion

Most of the NaCl ingested by marine birds is reabsorbed from renal filtrate and excreted by the cephalic salt glands as a hypertonic NaCl secretion (SGS). Ducks have salt glands and their kidney cells have melatonin receptors. Melatonin affects glomerular filtration rate and tubular uptake of sodium (Na(+)) in mammals. We hypothesized that (1) duck salt glands also have melatonin receptors and (2) melatonin affects extrarenal Na(+) secretion. Both hypotheses were accepted because putative melatonin receptors were identified by 2¿(125)Iĭodomelatonin binding in salt glands of Pekin ducks, Anas platyrhynchos, and because melatonin inhibited SGS in these ducks. Saline ingestion increased B(max), but not K(d), of salt gland receptors. The duration of NaCl infusion needed to stimulate SGS was positively related with preinfusion plasma melatonin concentration (¿mel(pl)). Raising ¿mel(pl) prior to NaCl infusion further delayed onset of secretion and decreased secretion rate and concentration without affecting plasma volume and Na(+) concentration. Abrupt increase in ¿mel(pl) during SGS immediately decreased the rate by 43%. Secretion rate remained lower than the control rate during the subsequent hour; secretion concentration was not affected. This is the first report of putative melatonin binding sites in avian salt glands. Melatonin slowed the onset of NaCl-induced salt gland secretion and decreased its rate.

Role of melatonin in the control of growth and growth hormone secretion in poultry

The pineal hormone melatonin controls reproduction of photoperiodic mammals and is an integral part of the circadian organization in birds. Recent findings indicate an involvement of this hormone also in more basic physiological processes, including growth, development, and aging. Melatonin may modulate growth in poultry through interaction with transcriptional factors, through interaction with hormones involved in growth control, and by modulation of energy metabolism and decreasing physical activity. Our studies showed that a single melatonin injection increased plasma growth hormone (GH) concentrations in the Japanese quail. Specific serotonin receptor blocker ketanserin did not preclude a stimulatory action of melatonin on GH synthesis. Serotonin agonist quipazine increased GH levels but failed to enhance the stimulatory effect of melatonin. Pretreatment with melatonin in drinking water did not affect the magnitude of the GH response to subcutaneous (s.c.) administration of thyrotropin releasing hormone (TRH) that considerably stimulated GH secretion. Present data suggest that melatonin modulates rather central neural pathways involved in the control of GH synthesis at the hypothalamic level than the sensitivity of the pituitary gland.

Cellular mechanisms of melatonin action

The pineal hormone melatonin is involved in photic regulations of various kinds, including adaptation to light intensity, daily changes of light and darkness, and seasonal changes of photoperiod lengths. The melatonin effects are mediated by the specific high-affinity receptors localized on plasma membrane and coupled to GTP-binding protein. Two different G proteins coupled to the melatonin receptors have been described, one sensitive to pertussis toxin and the other sensitive to cholera toxin. On the basis of the molecular structure, three subtypes of the melatonin receptors have been described: Mel1A, Mel1B, and Mel1C. The first two subtypes are found in mammals and may be distinguished pharmacologically using selective antagonists. Melatonin receptor regulates several second messengers: cAMP, cGMP, diacylglycerol, inositol trisphosphate, arachidonic acid, and intracellular Ca2+ concentration ([Ca2+]i). In many cases, its effect is inhibitory and requires previous activation of the cell by a stimulatory agent. Melatonin inhibits cAMP accumulation in most of the cells examined, but the indole effects on other messengers have been often observed only in one type of the cells or tissue, until now. Melatonin also regulates the transcription factors, namely, phosphorylation of cAMP-responsive element binding protein and expression of c-Fos. Molecular mechanisms of the melatonin effects are not clear but may involve at least two parallel transduction pathways, one inhibiting adenylyl cyclase and the other regulating phospholipide metabolism and [Ca2+]i.

Melatonin restores and enhances the human type B tonsillar lymphocyte subset in recurrent acute tonsillitis

Tonsils have a privileged situation in the immune system in that they are in touch with the environment. Melatonin is a hormone that is influenced by the circadian environmental variations of dark-light and is a modulator of the immune system. We have studied a group of thirty five children with recurrent acute tonsillitis that were submitted for tonsillectomy. Tonsillar lymphocyte subsets were determined before and after culture through flow cytometry in a tonsillar mononuclear suspension. After the culture, the lymphocyte subsets of type B suffered a decrease that was restored in the presence of melatonin or phytohemaglutinin, and even increased above the values of the control when the culture was accomplished in the presence of both substances. This process was specific for B cells, no occurrence for T lymphocytes or natural killer cells. Melatonin is found in the crossroads of the interaction of the microorganisms, pollens or inert substances with the tonsillar lymphocytes in the production of the immune defences. Further study is required on tonsillar pathology to explain its physiopathology and its possible therapeutic role.

Melatonin: receptor-mediated events that may affect breast and other steroid hormone-dependent cancers

Epidemiological studies have suggested a possible link between extremely low frequency electromagnetic fields (EMFs) and increased rates of certain cancers. One cancer that has been postulated to be associated with EMF exposure is breast cancer, for which increased rates have been reported among electricians. These cancer associations are weak, and the link to EMF exposures remains tenuous. Understanding the mechanisms by which EMFs could have biological effects will help in elucidating the risk, if any, from EMFs. One hypothesis that has received considerable attention involves reduction of melatonin levels by EMFs. This hypothesis suggests that loss of melatonin affects a variety of hormonal processes such as estrogen homeostasis and thereby may increase breast cancer rates. Since this theory was first presented, putative melatonin receptors have been cloned, providing new tools with which to examine melatonin's mechanism of action and the melatonin hypothesis. These receptors are found in nuclear and membrane fractions of cells. The nuclear receptors (retinoid Z receptors) are found both in the brain and in non-neural tissues, whereas the membrane-bound receptors are found primarily in neural tissue and have a higher affinity for melatonin. These receptors may control a variety of hormonal and immunological functions, including the release of gonadotropins from the hypothalamus and pituitary and 5-lipoxygenase activity in B lymphocytes. This Working Hypothesis briefly reviews our current knowledge of melatonin receptors and then provides theories on how the inactivation of melatonin receptors may cause cancer and suggests areas of research for addressing this question.

2-[125I]iodo-5-methoxycarbonylamino-N-acetyltryptamine: a selective radioligand for the characterization of melatonin ML2 binding sites

We now describe the preparation and characterization of a novel radioligand, 2-[125I]iodo-5-methoxy-carbonylamino-N-acetyltryptamine (2-[125I]MCA-NAT), with high affinity and pharmacological selectivity for melatonin ML2 receptor sites. 2-[125I]MCA-NAT was prepared by introducing an [125I]iodine molecule on carbon 2 of 5-MCA-NAT (5-methoxycarbonylamino N-acetyltryptamine), a selective melatonin ML2 receptor ligand. The specific binding (88%) of 2-[125I]MCA-NAT (50 pM) to whole washed hamster brain membranes showed rapid kinetics of association/dissociation, and was of high affinity and saturable (Kd value = 116 +/- 14 pM; Bmax value = 15.5 +/- 1.8 fmol/mg protein, n = 3). 2-[125I]MCA-NAT showed no affinity for melatonin ML1 receptors of chicken retina. Competition curves of various melatonin analogues for 2-[125I]MCA-NAT binding to hamster brain, testes and kidney were monophasic and showed a pharmacological order of affinities (Ki values for brain, nM) identical to that of the ML2 sites [2-iodomelatonin (0.77) > 6-chloro-2-methyl-melatonin (2.56) > 6-chloromelatonin (6.8) > prazosin (21.7) > or = N-acetylserotonin (23.3 nM) > or = 5-MCA-NAT (29.5) > or = melatonin (83.9) > luzindole (1687) > serotonin (2120)]. Affinity constants for competition of melatonin analogues on [125I]MCA-NAT binding to hamster brain, testes, and kidney correlated significantly [r = 0.962, P < 0.001, n = 9; r = 0.982, P < 0.0001, n = 13; r = 0.975, P < 0.0001, n = 9, respectively) with the affinities determined on 2-[125I]iodomelatonin binding to ML2 sites (hamster brain) but not to ML1 sites (chicken retina, r = 0.33, P > 0.05, n = 16). In conclusion, 2-[125I]MCA-NAT is a specific radioligand for the identification and characterization of ML2 binding sites in brain and peripheral tissues.

Expression of the melatonin receptor in Xenopus laevis: a comparative study between protein and mRNA distribution

Reverse transcription-polymerase chain reaction (RT-PCR) analysis performed on total RNA from different tissues of Xenopus laevis showed that the melatonin receptor gene cloned from dermal melanophores is expressed in the whole brain, skin, and retina, and that apart from the ovary, there is no expression in tissues having origin outside the central nervous system. Comparative studies using in vitro autoradiography and in situ hybridization demonstrated that the melatonin receptor is expressed with discrete allocation in Xenopus brain. Though the distribution pattern of the specific messenger RNA conforms well with that of the corresponding receptor protein, it is not always coincident.

Specific binding of 2-[125I]iodomelatonin by rat spleen crude membranes: day-night variations and effect of pinealectomy and continuous light exposure

Melatonin binding sites were characterized in rat spleen crude membranes. The specific binding of 2-[125I]iodomelatonin by spleen crude membranes fulfills all the criteria for binding to a receptor site. Thus, binding was dependent on time and temperature, stable, specific, and increased under constant light exposure and after pinealectomy. In competition studies, the specific binding of 2-[125I]iodomelatonin to spleen crude membranes was inhibited by increasing concentrations of native melatonin. Scatchard analysis showed that the data were compatible with the existence of two classes of binding sites: a high affinity site with a Kd of 0.53 nM and a binding capacity of 2.52 pM, and a low-affinity site with a Kd of 374 nM and binding capacity of 820 pM. Moreover, binding of 2-[125I]iodomelatonin exhibited day-night variations with the highest binding observed late during the light period, and the lowest binding was observed late at night. However, binding of 2-[125I]iodomelatonin to membranes remained high when animals were kept under light exposure at night. Results support the hypothesis of a regulatory role of melatonin on the immune system in which melatonin downregulates its own binding site.

Sensitivity of human peripheral blood mononuclear leukocytes to visible light

Overnight light exposure of cultured human peripheral blood mononuclear leukocytes [PBML], significantly increased basal [3H]thymidine incorporation and upon stimulation with phytohemagglutinin [PHA]. Melatonin (10(-9) to 10(-5) M) enhanced the light-induced increase of [3H]thymidine incorporation, while serotonin (10(-9) to 10(-7) M) stimulated [3H]thymidine incorporation in the dark. The wavelengths responsible of this effect were restricted to the blue-green zone of the spectrum. The stimulatory effect of visible light on PHA-induced DNA replication had a circannual rhythm, being maximal during winter. In winter, white light also reduced melatonin and serotonin binding to PBML membranes and switched the PBML indole metabolism towards serotonin and 5-hydroxy-indole-acetic acid [HIAA] synthesis, with a concomitant decrease of melatonin production.

Immunomodulatory role of melatonin: specific binding sites in human and rodent lymphoid cells

This paper reviews the evidence that supports the hypothesis of the existence of specific binding sites for melatonin on immune cells. These binding sites have been described in human blood lymphocytes and granulocytes, and thymus, spleen, and bursa of Fabricius from different rodents and birds. The dissociation constant values of these binding sites are in the 0.1-1 nM range, suggesting that melatonin may play a physiological role in lymphocyte regulation. Moreover, melatonin binding sites appear to be modulated by guanine nucleotides. Therefore, in addition to other mechanisms described for the regulation of immune function by melatonin, a direct mechanism of regulation can be involved via binding of melatonin by immunocompetent cells.

Specific binding of 2-[125I]iodomelatonin by rat splenocytes: characterization and its role on regulation of cyclic AMP production

In the present paper we show that pineal hormone melatonin interacts with rat splenocytes through high-affinity binding sites. Binding of 2-[125I]iodomelatonin ([125I]MEL) by splenocytes fulfills all criteria for binding to a receptor site. Binding exhibited properties such as dependence on time and temperature as well as reversibility, saturability, high affinity, specificity, and increased under constant light exposure. Results suggest binding to a single class of binding sites without cooperative interactions. The dissociation constant (Kd) for the single site was 0.34 nM with a binding capacity of 2.25 fmol/10(7) cells. These data are in close agreement with data obtained from kinetic studies, in which the kinetically derived value of the dissociation constant was 0.20 nM. The affinity of these binding sites suggests that they may recognize the physiological concentrations of melatonin in serum. Moreover, pharmacological doses of melatonin also inhibited cyclic AMP production stimulated by forskolin, a potent activator of adenylate cyclase system. The demonstration of [125I]MEL binding sites in the spleen, in addition to those described in blood mononuclear cells and thymus, provides evidence to support a direct mechanism of action of melatonin on immune system.

A comparative study of picomolar affinity 2-[(125)I]iodomelatonin binding sites in the hearts of three salmonid species

The hearts of three cultured salmonid species, collected at either mid-light or mid-dark were studied for their binding to 2-[(125)I]iodomelatonin, a specific melatonin agonist. The binding was saturable, reversible, and highly specific. The equilibrium dissociation constant (Kd) ranged from 30.1 ± 3.0 pmole 1(-1) in Arctic charr (Salvelinus alpinus) to 40.5 ± 2.3 pmole 1(-1) in rainbow trout (Oncorhynchus mykiss) indicating a high binding affinity. The maximum density of binding (Bmax) was at the low femtomolar level of 0.57 to 0.87 fmole mg(-1) protein. Higher Bmax appeared to be demonstrated in the mid-light samples when compared to the mid-dark samples but the difference was not significant (p > 0.05). Competition study with various indoles showed the following order of potency: 2-iodomelatonin > melatonin > 6-chloromelatonin ≫ N-acetylserotonin ⋙ serotonin. Guanosine 5'-O-(3-thiotriphosphate) (GTPγS) strongly inhibited the binding (IC50 = 0.66 μmole 1(-1)) in the rainbow trout heart, suggesting that these binding sites belong to the superfamily of G-protein linked receptors. Our results suggest the presence of melatonin receptors in the fish heart. In addition, there was no marked intraspecies differences in Kd, Bmax and specificity that could be correlated with the phylogeny or life history of the salmonid species.

Identification and characterization of 2[125I]-iodomelatonin binding sites in the rat epididymis

Putative melatonin receptors in different parts of the male reproductive system of rats (Sprague-Dawley), mice (ICR), hamsters (Syrian) and guinea pigs (Dunkin-Hartley), rat epididymal sperm, and boar and human semen were studied by a radioreceptor assay using 2[125I]iodomelatonin as the radioligand. There was limited or no detectable binding of 2[125I]iodomelatonin to membrane preparations of rat testis, seminal vesicles, prostate, or sperm from rat, human, and boar. However, significant bindings of 2[125I]iodomelatonin to the epididymides of rat, mouse, hamster, and guinea-pig were demonstrated. The relative binding capacities of 2[125I]iodomelatonin to the distal epididymal segment in different rodent species was of the order rat mouse hamster guinea pig. The relative number of binding sites was much lower in the proximal segment than in the distal segment of epididymis. 2[125I]iodomelatonin binding to the distal segment of rat epididymis was studied in detail. The binding sites fulfilled all criteria for a receptor site; being stable, saturable, reversible, and of high affinity. The binding had an equilibrium dissociation constant (Kd) of 62.6 +/- 7.79 pmol/l (n = 7) and a density (Bmax) of 1.55 +/- 0.16 fmol/mg protein (n = 7). The Hill coefficient approached 1.0, suggesting a single class of 2[125I]iodomelatonin binding sites. Pharmacological studies revealed that these 2[125I]iodomelatonin binding sites were specific for melatonin receptors. In addition, there was an age-related change in the 2[125I]iodomelatonin binding sites in the rat distal epididymal segment. The binding increased from a lower value in 1-month-old rats to a higher adult value in the 1 1/2- to 24-month-old animals.(ABSTRACT TRUNCATED AT 250 WORDS)

Localization and characterization of [125I]iodomelatonin binding sites in duck gonads

The characterization and localization of [125I]iodomelatonin binding sites in the gonads advances the understanding of possible regulatory sites of melatonin action. With the availability of [125I]iodomelatonin as a biologically active radioligand, our study utilized a combined approach of autoradiography for anatomical resolution together with an established radioligand binding assay to assess mid-light [125I]iodomelatonin binding in the testes and ovaries of ducks. In the autoradiography study, specific [125I]iodomelatonin binding was shown to be homogeneous throughout the testes, while in the ovaries, specific [125I]iodomelatonin binding appeared to be concentrated around the follicle. Radioligand binding assay results indicated a single class of binding sites with the maximum number of [125I]iodomelatonin binding sites measured at 1.91 +/- 0.70 fmol/mg protein in testicular membrane and 4.54 +/- 0.64 fmol/mg protein in ovarian membrane. [125I]Iodomelatonin binding affinity, characterized by equilibrium dissociation constants of 29 +/- 6 pmol/L in testicular membrane and 53 +/- 9 pmol/L in ovarian membrane, was in accordance with circulating melatonin levels, suggesting an appropriate concentration for eliciting a physiological response. [125I]Iodomelatonin binding in duck gonads satisfied all the criteria for a binding site, being rapid, stable, saturable, reversible, specific, and of high affinity, and may indicate a direct pineal-gonadal connection.

Differential effects of guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S) on the 2-[125I]iodomelatonin binding sites in the chicken bursa of Fabricius and spleen

Effects of 10 and 50 mumol/l guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S) on 2-[125I]iodomelatonin binding in the chicken bursa of Fabricius and spleen were tested. In the chicken bursa of Fabricius, GTP gamma S increased the Kd of 2-[125I]iodomelatonin binding sites without affecting the Bmax value. In contrast, GTP gamma S caused both an increase in Kd and a reduction in Bmax of 2-[125I]iodomelatonin binding sites in the chicken spleen. Our results suggest the existence of subtypes of melatonin receptors with different receptor-G protein-effector complexes in the avian primary and secondary lymphoid systems.

Characterization of high-affinity melatonin binding sites in purified cell nuclei of rat liver

High-affinity 2-125I-iodomelatonin binding sites in homogenates of purified cell nuclei from rat liver were localized and characterized using biochemical binding techniques. Binding at these sites was found to be rapid, reversible, saturable, and to demonstrate pharmacological selectivity. At 0 degrees C, binding reached equilibrium in about 10 min. Scatchard analysis of the data at equilibrium revealed a single class of binding sites with a dissociation constant of KD = 190 +/- 47 pM, Bmax = 9.8 +/- 0.6 fmol/mg protein, and a Hill coefficient of nH = 1.02 +/- 0.034. Kinetic analysis of the association and dissociation curves indicated a kinetic KD = 148 +/- 41 pM, which is in good agreement with the value obtained at equilibrium. The specific binding of 2-125I-iodomelatonin (45 pM) (0.51 +/- 0.04 fmol/mg protein) was significantly improved (0.79 +/- 0.04 fmol/mg protein) when the homogenates of purified liver cell nuclei were preincubated with DNase (2 micrograms/ml at 37 degrees C for 20 min) before being used in binding experiments. After the addition of either proteinase K or trichloroacetic acid to DNase-treated purified cell nuclear homogenates, the specific binding disappeared. This suggests that the specific binding of 2-125I-iodomelatonin in liver cell nuclei is associated with nuclear protein. Competition experiments show that N-acetyl-serotonin (Ki = 81.3 nM) was more potent than 5-hydroxytryptamine (Ki > 1 microM) and 5-methoxytryptamine (Ki >> 10 microM) in inhibiting 2-125I-iodomelatonin binding (Ki melatonin = 146 pM). These data indicate that specific 2-125I-iodomelatonin binding sites exist in the cell nuclei of rat liver, and that they may comprise a locus for the intracellular action of melatonin. The correlation between the KD and Bmax values with melatonin concentrations in nuclei suggest that these binding sites may be a physiological melatonin receptor, which could explain the described genomic effects of the pineal hormone.

Specific 2-[125I]iodomelatonin binding sites in the duck adrenal gland

Using 2-[125I]iodomelatonin as the radioligand, putative melatonin receptors in the duck adrenal gland were investigated. 2-[125I]Iodomelatonin binding to the membrane preparations of duck adrenals collected at mid-light was specific, rapid, saturable, stable, reversible and of high affinity. Scatchard analyses showed one class of binding sites with an equilibrium dissociation constant of 27.4 +/- 2.9 pmol/l and a maximum number of binding sites of 3.38 +/- 0.26 fmol/mg protein. Binding of 2-[125I]iodomelatonin in different subcellular fractions demonstrated the following descending order of density: mitochondrial > nuclear > microsomal >>> cytosol. Pharmacological studies indicated that these sites were highly specific to melatonin. As 2-[125I]iodomelatonin is a specific agonist of melatonin, it is proposed that the sites studied are adrenal melatonin receptors.

Modulation of 2[125I]iodomelatonin binding sites in the guinea pig spleen by melatonin injection is dependent on the dose and period but not the time

Effects of dose, time and period of melatonin injection on 2[125I]iodomelatonin binding sites in the guinea pig spleen were studied. Guinea pigs (Dunkin-hartley), kept under 12h light/12 h darkness, were given daily intraperitoneal injections of either vehicle or 0.01, 0.1 or 1 mg melatonin/kg body weight in either early (1 hour after onset of light period) or late light period (1 hour before offset of light period) for 2 or 7 days. To study the effect of opioid antagonist on the binding, intraperitoneal injections of 2 or 20 mg naltrexone/kg body weight alone or together with 0.1 mg melatonin/kg body weight was given daily in late light period for 2 days. 2[125I]Iodomelatonin binding assays were performed on spleen membrane preparations and radioimmunoassays of melatonin levels were carried out in serum and pineal glands collected during mid-light. High dose (1 mg/kg body weight) of melatonin injection elevated the mid-light serum melatonin levels without affecting pineal melatonin levels. Early light injection group had a higher mid-light serum melatonin level. Melatonin injection for 2 days at either time points caused a dose-dependent decrease in Bmax and increase in Kd of 2[125I]iodomelatonin binding sites in the spleen. The response was independent of the time of injection. A greater suppression of binding was achieved by injecting melatonin for 7 days. Naltrexone did not affect the binding by itself and was not able to reverse the melatonin-induced suppression of binding in the spleen. The modulation of the splenic 2[125I]iodomelatonin binding sites by exogenous melatonin suggests that melatonin may act directly on the immune system to affect its function.

G-protein linked melatonin binding sites in the chicken lung

[125I]Iodomelatonin binding was first demonstrated in the chicken lung membrane preparations. The binding was saturable, reversible, rapid, and of high affinity. The sites of binding distributed widely in different subcellular fractions except the cytosol fraction. Scatchard plots are linear indicating a dissociation constant (Kd) of 8.11 +/- 0.73 pmol/l and a maximum number of binding sites of 1.29 +/- 0.16 fmol/mg protein (n = 9). The Kd estimated from the kinetic study was 11.2 pmol/l. Guanosine 5'-O-(3-thiotriphosphate) significantly increased the Kd values while the density of binding sites was not affected indicating that the binding sites may be linked to a guanine nucleotide binding protein.

Clinical aspects of the melatonin action: impact of development, aging, and puberty, involvement of melatonin in psychiatric disease and importance of neuroimmunoendocrine interactions

During the last decade we have learned much on physiological changes in the secretion of the pineal hormone melatonin (MLT) in man. Reportedly, there is little or no MLT secreted before age 3 months. Then MLT production commences, becomes circadian, and reaches highest nocturnal levels at the age of 1-3 years. During all of childhood nocturnal peak levels drop progressively by 80% until adult levels are reached. This alteration appears to be the consequence of increasing body size in face of constant MLT production during childhood. The biological significance of this MLT alteration is presently unknown. Because of conceptual considerations, major depressive syndrome (MDS) and seasonal affective disorder (SAD) have been in the focus of pineal research for several years. Although in these disorders alterations in MLT levels could not be substantiated, light therapy, a consequence of this research, was discovered as an effective treatment for SAD and perhaps for MDS. In addition, there is some recent evidence for low MLT levels in schizophrenia. Finally, the potential effect of MLT in neuroimmunoendocrine interactions is presently explored. Reportedly, in vitro studies and animal experiments give evidence for a modulatory role of MLT in the immune response. However, the exact way of this possible action of MLT remains to be clarified. Clinical studies are too scant for a meaningful estimation of MLT's involvement in human neuroimmunoendocrine interactions.

Characteristics of 2-[125I]iodomelatonin binding sites in the pigeon spleen and modulation of binding by guanine nucleotides

2-[125]Iodomelatonin binding sites in membrane preparations of pigeon spleen have been characterized. The binding was stable, saturable, reversible, and of high affinity. Rosenthal and Hill analyses showed that the radioligand-receptor interaction involved a single class of binding sites. Analysis of the binding results of spleens collected during mid-light revealed an equilibrium dissociation constant (Kd) of 36.6 +/- 4.8 pmol/l (mean +/- sem, n = 10) and a maximum density (Bmax) of 2.3 +/- 0.2 fmol/mg protein. There was no significant difference in the Kd (46.9 +/- 5.0 pmol/l) or the Bmax values (2.4 +/- 0.3 fmol/mg protein) for spleens collected during mid-dark (n = 9), although the mid-dark serum and pineal melatonin levels were significantly higher (P < 0.05) than the corresponding mid-light values. Kinetic analysis showed a Kd of 8.6 +/- 2.0 pmol/l (n +/- 4), in agreement with that derived from the saturation studies. Except for inhibition by 2-iodomelatonin, melatonin, 6-chloromelatonin, 6-hydroxymelatonin and N-acetylserotonin, the other indoles or neurotransmitters tested have little inhibition on the binding. In addition, guanosine 5'-O-(3-thiophosphate) (GTP gamma S), a nonhydrolysable analog of GTP, was found to inhibit the binding in a dose-dependent manner. Saturation studies revealed that this is due to a decrease in both the affinity and density of the binding sites. These data suggest that a single type of melatonin receptor is found in the pigeon spleen and that the site is coupled to a guinine nucleotide binding protein (G-protein). Our findings support a direct pineal melatonin action on the immune system.

[125I]-labelled iodomelatonin binding sites in the duck bursa of Fabricius: binding characteristics and diurnal variation

Melatonin receptors in membrane preparations of the duck bursa of Fabricius were studied by using [125I]-labelled iodomelatonin as the radioligand. Specific binding of [125I]-labelled iodomelatonin in the membrane preparations of bursa was stable, saturable, reversible and of high affinity. Scatchard analysis of the specific binding revealed an equilibrium dissociation constant (Kd) of 48.5 +/- 7.4 pmol/l and a total number of binding sites (Bmax) of 1.38 +/- 0.12 fmol/mg protein at mid-light. A diurnal study showed that the Bmax of [125I]-labelled iodomelatonin binding sites at mid-light was 94.4% higher (P < 0.05) than that at mid-dark. There was no significant difference in the mid-light and mid-dark Kd values. The Kd value determined by kinetic analysis was 42.0 +/- 9.3 pmol/l at mid-light. The pharmacological characteristics indicated that [125I]-labelled iodomelatonin binding sites are highly specific for melatonin. Our results suggest that the bursa is a target organ of melatonin action.

High affinity specific binding of 2-[125I]iodomelatonin by spleen membrane preparations of chicken

The binding sites for 2-[125I]iodomelatonin in chicken spleens were characterized. The binding was rapid, stable, saturable, reversible, and of high affinity. Both melatonin and 6-chloromelatonin strongly inhibited the binding. The dissociation constant (Kd) obtained from the Scatchard analysis was 31.4 +/- 5.19 pmol/l (3-weeks old, n = 4), which was in good agreement with the Kd (50.6 pmol/l) calculated from the kinetic study. The maximum number of binding sites (Bmax) was 1.09 +/- 0.11 fmol/mg protein (3-weeks old, n = 4). Twelve 11-week-old chicks were killed in two groups at mid-light or mid-dark. Saturation studies indicated no significant difference (P greater than 0.05) in the Kd between mid-light (42.1 +/- 3.9 pmol/l) and mid-dark (31.6 +/- 4.9 pmol/l). The maximum number of binding sites (Bmax) at mid-light and mid-dark were 1.52 +/- 0.16 and 1.35 +/- 0.08 fmol/mg protein, respectively, with no significant variation (P greater than 0.05) recorded. However, when the whole spleen was taken into consideration, the Bmax per spleen protein of the mid-light samples (253 +/- 36 fmol/spleen protein) was significantly greater than that (129 +/- 16 fmol/spleen protein) of the mid-dark samples (P less than 0.05). This indicated that in our study a diurnal rhythm of the total number of 2-[125I]iodomelatonin binding sites might exist in the chicken spleen.

2[125I]iodomelatonin binding sites in spleens of guinea pigs

2-[125I]Iodomelatonin was found to bind specifically to the membrane preparations of the spleens of guinea pigs with high affinity. The binding was rapid, stable, saturable and reversible. Scatchard analysis of the binding assays revealed an equilibrium dissociation constant (Kd) of 49.8 +/- 4.12 pmol/l and binding site density (Bmax) of 0.69 +/- 0.082 fmol/mg protein at mid-light (n = 10). There was no significant change in the Kd (41.8 +/- 3.16 pmol/l) or the Bmax (0.58 +/- 0.070 fmol/mg protein) at mid-dark (n = 10). Kinetic analysis showed a Kd of 23.13 +/- 4.81 pmol/l (mean +/- SE, n = 4), in agreement to that derived from the saturation studies. The 2-[125I]iodomelatonin binding sites have the following order of potency: 2-iodomelatonin greater than melatonin greater than 6-chloromelatonin much greater than N-acetylserotonin, 6-hydroxymelatonin greater than 5-methoxytryptamine, 5 methoxytryptophol greater than serotonin, 5-methoxyindole-3-acetic acid greater than 5-hydroxytryptophol, 3-acetylindole, 1-acetylindole-3-carboxyaldehyde, L-tryptophan greater than tryptamine, 5-hydroxyindole-3-acetic acid. Differential centrifugation studies showed that the binding sites are localized mainly in the nuclear fraction (65.5%), the rest are distributed in the microsomal fraction (17.4%), mitochondrial fraction (14.7%) and cytosolic fraction (0.3%). The demonstration of 2-[125I]iodomelatonin binding sites in the spleen suggests the presence of melatonin receptors and a direct mechanism of action of melatonin on the immune system.